As of June 30, Tyra had cash, cash equivalents, and marketable securities of $296.3M. Tyra’s current cash, cash equivalents and marketable securities are expected to allow Tyra to execute on its plans through at least 2027. “We see significant opportunity to transform the treatment of bladder cancer and skeletal dysplasia by precisely targeting FGFR3. With BEACH301 open for enrollment and SURF302 advancing in intermediate-risk non-muscle invasive bladder cancer, we’re building a franchise with dabogratinib around the power of FGFR3 selectivity and sensitivity,” said Todd Harris, CEO. “Backed by a strong balance sheet, we’re well positioned to deliver meaningful Phase 2 readouts in SURF302 and BEACH301.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences announces presentation on TYRA-300 preclinical results at ENDO
- Promising Outlook for Tyra Bioscience: Buy Rating Driven by TYRA-300’s Potential in NMIBC Treatment
- Tyra Bioscience Launches Phase 2 Study for TYRA-300
- Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300